Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.558 estudios en Oncología (médica) (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. A Study of Nab-Paclitaxel as Maintenance Treatment After Cisplatin-Based Chemotherapy and Surgery for Patients with High-Risk Bladder Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate nab-paclitaxel as maintenance therapy after cisplatin-based chemotherapy and surgery in treating patients with high-risk bladder cancer. Maintenance therapy, such as paclitaxel albumin-stabilized nanoparticle formulation, can help keep cancer from coming back after it has disappeared following initial chemotherapy. Profiling of Lung Cancer for Identification of Treatment Targets and Strategies Jacksonville, Fla. The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) tumor samplesand to investigate the correlation between genetic alteration/mutation status and tumor immune micro-environment. Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy with Adjuvant PCV Chemotherapy in Patients with Anaplastic Glioma or Low Grade Glioma Rochester, Minn., Jacksonville, Fla. The purpose of this study is to evaluate whether radiation therapy with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma. A Study to Assess Financial Burden and Its Impact on Quality of Life in Patients with Plasma Cell Disorders Rochester, Minn. The purpose of this study is to evaluate the magnitude of financial toxicity in newly diagnosed and relapsed multiple myeloma (MM) and amyloidosis (AL) patients. International Hepatobiliary Neoplasia Registry and Biorepository Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. This study is being done to: 1. Create a registry of patients having or at risk for cancer of the liver or bile ducts (also known as hepatocellular carcinoma or cholangiocarcinoma), or gallbladder cancer, and those individuals who have normal risk factors in order to improve the ability to diagnose and treat these cancers. We will use information in the medical record in this registry including how far advanced the cancer is (stage) and what treatments are used to treat the cancer. 2. A second purpose of this study is to obtain blood and tissue samples from participants having or at risk for developing cancer of the liver or bile ducts or gallbladder cancer to be used for future research testing. Future testing may include searching for changes in the genetic material (DNA and other molecules). First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Rochester, Minn., Jacksonville, Fla. The primary objective of this study is to determine the confirmed investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) in patients with higher sodium-dependent phosphate transport protein 2b (NaPi2b) expressing platinum-resistant high-grade serous ovarian cancer (HGSOC), including cancers of ovarian, fallopian tube or primary peritoneal origin) Note: Mayo Clinic is only participating in the Phase 2 - Cohort 3 (UPLIFT) portion of the study. Mayo Clinic will not be participating in the QTC sub-study. Study of RP-6306 With FOLFIRI in Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity. DNA Methylation in Adenocarcinoma of the Prostate: Tissue Validation of Biomarkers and Pilot Testing in Blood Rochester, Minn. The study will be performed in two phases: Phase I will be performed for biologic validation of marker candidates from a discovery cohort and phase II will be performed to evaluate the discrimination (sensitivity/specificity) of best candidate markers when assayed from blood of cases with CAP and controls without history of cancer. Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma Rochester, Minn. The purpose of this study is to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. Effect of Agent Orange Exposure on Endocrine Tumor Aggressiveness Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The intent is to collect relevant clinical data on patients exposed to Agent Orange plus assessment of the tissue for genetic mutations known to be associated with growth of thyroid cancer and pituitary tumors and report our findings as a descriptive case series. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 99 Ir a página 1010 Ir a página 1111 Ir a página 1212 Ir a página 1313 SiguientePróxima página Solicite una consulta Conocimientos y categoríasInvestigación May 09, 2023 Comparte en: FacebookTwitter Mayo Clinic en Rochester, Minnesota, Mayo Clinic en Jacksonville, Florida y Mayo Clinic en Phoenix y Scottsdale, Arizona, han sido reconocidas entre los mejores hospitales oncológicos en el país durante el período 2023-2024 por U.S. News and World Report. Lee más sobre este gran honor. Oncología (médica)Página inicialdel departamentoSeccionesDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones ORG-20180179 Centros y departamentos médicos Oncología (médica)